Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption
Fig 8
The proportion of per protocol participants showing ‘Vacc-4x T-cell proliferation Responder’ profiles in CD4 and CD8 T-cell subpopulations for the 2012/1 study and wk52 of the 2007/1 study.
The sample size was too small for a comparison of ‘Vacc-4x T-cell proliferation Responders’ between wk28 in the 2012/1 study and wk52 in the 2007/1 study in participants that had data for both time points (CD4 n = 6; CD8 n = 7).